Towards Healthcare
Retinitis Pigmentosa Market Size to Capture $27.17 Bn by 2034

Retinitis Pigmentosa Market Patient-Centered Care Models and Strategies

According to market projections, the retinitis pigmentosa sector is expected to grow from USD 14.89 billion in 2024 to USD 27.17 billion by 2034, reflecting a CAGR of 6.2%. In 2023, Autosomal Recessive RP dominated with 65% market share, but gene therapy is gaining traction at 23%, bringing new hope. North America leads the market, yet Asia Pacific is the fastest-growing region, signaling a potential shift in the landscape for Retinitis Pigmentosa treatment.

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Retinitis Pigmentosa Market Assessment

  • Overview
  • Global Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Autosomal Dominant RP
    • Autosomal Recessive RP
    • X-linked RP
  • Global Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Vit A Supplements
    • Gene Therapy
    • Vit A Supplements
    • Gene Therapy
    • Retinal Implants
    • Low Vision Aids
    • Surgery
    • Others
  • Global Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa

North America Retinitis Pigmentosa Market Assessment

  • Overview
  • North America  Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Autosomal Dominant RP
    • Autosomal Recessive RP
    • X-linked RP
  • North America Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Vit A Supplements
    • Gene Therapy
    • Vit A Supplements
    • Gene Therapy
    • Retinal Implants
    • Low Vision Aids
    • Surgery
    • Others

Europe Retinitis Pigmentosa Market Assessment

  • Overview
  • Europe Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Autosomal Dominant RP
    • Autosomal Recessive RP
    • X-linked RP
  • Europe Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Vit A Supplements
    • Gene Therapy
    • Vit A Supplements
    • Gene Therapy
    • Retinal Implants
    • Low Vision Aids
    • Surgery
    • Others

Asia Pacific Retinitis Pigmentosa Market Assessment

  • Overview
  • Asia Pacific Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Autosomal Dominant RP
    • Autosomal Recessive RP
    • X-linked RP
  • Asia Pacific Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Vit A Supplements
    • Gene Therapy
    • Vit A Supplements
    • Gene Therapy
    • Retinal Implants
    • Low Vision Aids
    • Surgery
    • Others

Latin America Retinitis Pigmentosa Market Assessment

  • Overview
  • Latin America Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Autosomal Dominant RP
    • Autosomal Recessive RP
    • X-linked RP
  • Latin America Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Vit A Supplements
    • Gene Therapy
    • Vit A Supplements
    • Gene Therapy
    • Retinal Implants
    • Low Vision Aids
    • Surgery
    • Others

Middle East and Africa Retinitis Pigmentosa Market Assessment

  • Overview
  • Middle East and Africa Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Autosomal Dominant RP
    • Autosomal Recessive RP
    • X-linked RP
  • Middle East and Africa Retinitis Pigmentosa Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Vit A Supplements
    • Gene Therapy
    • Vit A Supplements
    • Gene Therapy
    • Retinal Implants
    • Low Vision Aids
    • Surgery
    • Others

Company Profiles

  • Novartis
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Roche (Spark Therapeutics Inc)
  • MeiraDx
  • Astellas Pharma Inc.
  • Clino Corporation
  • Gensight Biologics
  • InFlectis BioScience
  • Bausch Health Companies Inc.
  • Adverum Biotechnologies
  • ReGenx Biosciences

Conclusion & Recommendations

  • Insight Code: 5114
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: March 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

Retinitis Pigmentosa (RP) is a genetic disorder affecting the retina, leading to the gradual loss of photoreceptor cells. Symptoms include decreased night and peripheral vision, progressing to tunnel vision, and potential blindness.

Creating innovative retinitis pigmentosa treatments, like gene therapy and stem cell therapy, is complex and expensive.

The North American region leads the retinitis pigmentosa market.

Center for Disease Control and Prevention, World Health Organization, National Institute of Health, National Eye Health Education Program.
Any Questions